NASDAQ · Biotechnology · USD

Lakewood-Amedex Biotherapeutics, Inc. (LABT) Stock Analysis

Lakewood-Amedex Biotherapeutics, Inc. (LABT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

LABT

$1.88

−$0.02 (−1.05%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LABT with… →

LABT Key Statistics

As of Sep 4, 2026

Trading

Open: $1.88
Previous Close: $1.90
Day's Range: 1.87–1.98
52-Week Range: 1.66–98.20
Volume: 90.20K

Valuation

Market Cap: $4.46M
P/E Ratio: unprofitable
EPS (ttm): −3.22

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$3.85M
Profit margin: 0.00%
Shares Outstanding: 2.37M

Dividend and dates

Avg Volume: 1.79M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

LABT Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$3.85M	—
2024	$0.00	−$4.86M	—
2023	$0.00	−$8.28M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$3.77M	−$3.85M	—
2024	$0.00	—	−$4.03M	−$4.86M	—
2023	$0.00	—	−$8.64M	−$8.28M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LABT Valuation vs Biotechnology Median

Median of 656 stocks

Metric	LABT	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Lakewood-Amedex Biotherapeutics, Inc. (LABT) is capitalised at $4.46M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 5 employees.

The 52-week range on file runs from $1.66 to $98.20. The most recent close on file for LABT is $1.88, dated September 4, 2026. That is −$0.02 (−1.05%) against the previous close. The latest close sits 13.25% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $3.85M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −3.22.

Across the 3 fiscal years on file, revenue moves from $0.00 in 2023 to $0.00 in 2025. Of those 3 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Growth & Income

No dividend is on file for LABT.

So far in 2026 the price is −97.83%.

Peer Comparison

Lakewood-Amedex Biotherapeutics, Inc. (LABT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Lakewood-Amedex Biotherapeutics, Inc.	LABT	$4.46M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Lakewood-Amedex Biotherapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Lakewood-Amedex Biotherapeutics, Inc.

Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.

Visit website →